# US 2026/0265203 A1 · Crystal forms of nitrogen-containing spiro compound, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265203 A1
- Document ID: US20260265203A1
- Status: Published application
- Kind: A1
- Application number: 19/166,500
- Filed: 2024-03-28
- Published: 2026-09-10
- Earliest claimed: 2023-03-28
- Assignees: Wuhan Createrna Science and Technology Co., Ltd.
- Applicants: Wuhan Createrna Science and Technology Co., Ltd.
- Inventors: Qinquan HU; Jun LOU; Liang WANG; Yihan ZHANG
- Web page: https://patentgrep.com/patent/US20260265203A1

## CPC

- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07D 221/20: Spiro-condensed ring systems
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- A61P 37/02: Immunomodulators
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed in the present invention are crystal forms of a nitrogen-containing spiro compound, a preparation method therefor and the use thereof. Provided in the present invention are a crystal form I and a crystal form II of a nitrogen-containing spiro compound as shown in formula A. Herein, crystal form I has an X-ray powder diffraction pattern comprising diffraction peaks at 5.67±0.20°, 11.37±0.20°, 16.69±0.20°, 17.32±0.20° and 19.73±0.20° 2θ, as determined by using Cu-Kα radiation crystal form II has an X-ray powder diffraction pattern comprising diffraction peaks at 11.32±0.20°, 11.70±0.20°, 11.93±0.20°, 18.03±0.20°, 18.81±0.20° and 19.17±0.20° 2θ, as determined by using Cu-Kα radiation. The crystal forms of the nitrogen-containing spiro compound of the present invention have good stability, an inhibitory activity on complement factor D, a good inhibitory effect on rabbit erythrocyte hemolysis, and relatively high in-vivo exposure and relatively high oral bioavailability.

## Claims

### Claim 1

A crystal form I of a nitrogen-containing spiro compound of formula A, wherein the crystal form I has an X-ray powder diffraction pattern comprising diffraction peaks at 5.67±0.20°, 11.37±0.20°, 16.69±0.20°, 17.32±0.20°, and 19.73±0.20°, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles;

### Claim 2 (depends on 1)

The crystal form I according to claim 1, wherein the crystal form I satisfies one or more of the following conditions:
(1) the X-ray powder diffraction pattern of the crystal form I, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, further comprises diffraction peaks at one or more of the following positions: 12.01±0.20°, 13.89±0.20°, 17.05±0.20°, 19.42±0.20°, 23.41±0.20°, and 27.86±0.20°;
(2) the X-ray powder diffraction pattern of the crystal form I, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks at one or more of the following positions: 12.01±0.20°, 13.89±0.20°, 17.05±0.20°, 18.04±0.20°, 18.43±0.20°, 19.42±0.20°, 22.94±0.20°, 23.41±0.20°, 26.01±0.20° and 27.86±0.20°;
(3) the X-ray powder diffraction pattern of the crystal form I, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks at 5.67±0.20°, 11.37±0.20°, 12.01±0.20°, 13.89±0.20°, 16.69±0.20°, 17.05±0.20°, 17.32±0.20°, 18.04±0.20°, 18.43±0.20°, 19.42±0.20°, 19.73±0.20°, 22.94±0.20°, 23.41±0.20°, 26.01±0.20°, and 27.86±0.20°;
(4) the X-ray powder diffraction pattern of the crystal form I, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks at positions as shown in the following table:
Position in
No.
2θ (°)
1
3.50
2
5.67
3
6.88
4
9.13
5
11.37
6
12.01
7
12.37
8
13.89
9
14.20
10
15.05
11
16.69
12
17.05
13
17.32
14
18.04
15
18.43
16
18.69
17
19.42
18
19.73
19
20.98
20
21.17
21
21.80
22
22.32
23
22.94
24
23.41
25
24.03
26
24.23
27
24.45
28
25.00
29
25.45
30
26.01
31
27.19
32
27.36
33
27.86
34
28.76
35
29.57
36
31.29
37
33.18
38
33.62
39
35.40
40
35.87
41
36.75
42
38.23
43
39.71;
(5) the X-ray powder diffraction pattern of the crystal form I, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks with positions and relative intensities as shown in the following table:
Position in
Relative
No.
2θ (°)
intensity
1
3.50
3.00%
2
5.67
45.80%
3
6.88
3.00%
4
9.13
6.90%
5
11.37
38.70%
6
12.01
25.90%
7
12.37
6.50%
8
13.89
11.90%
9
14.20
4.10%
10
15.05
2.40%
11
16.69
36.70%
12
17.05
25.60%
13
17.32
28.90%
14
18.04
10.70%
15
18.43
10.30%
16
18.69
5.00%
17
19.42
13.70%
18
19.73
100.00%
19
20.98
2.30%
20
21.17
6.30%
21
21.80
1.40%
22
22.32
3.60%
23
22.94
10.60%
24
23.41
25.50%
25
24.03
3.40%
26
24.23
5.90%
27
24.45
3.40%
28
25.00
1.80%
29
25.45
2.30%
30
26.01
10.40%
31
27.19
1.80%
32
27.36
1.50%
33
27.86
15.00%
34
28.76
2.80%
35
29.57
4.70%
36
31.29
3.40%
37
33.18
0.90%
38
33.62
2.00%
39
35.40
0.90%
40
35.87
1.60%
41
36.75
0.60%
42
38.23
0.60%
43
39.71
1.00%;
(6) the crystal form I has a differential scanning calorimetry pattern comprising an endothermic peak at 231.1±2° C.; and
(7) the crystal form I has a thermogravimetric analysis pattern showing no weight loss before 200±2° C.

### Claim 3 (depends on 2)

The crystal form I according to claim 2, wherein the crystal form I satisfies one or more of the following conditions:
(1) the X-ray powder diffraction pattern of the crystal form I, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, is substantially as shown in FIG. 2;
(2) the differential scanning calorimetry pattern of the crystal form I is substantially as shown in FIG. 3; and
(3) the thermogravimetric analysis pattern of the crystal form I is substantially as shown in FIG. 3.

### Claim 4

A crystal form II of a nitrogen-containing spiro compound of formula A, wherein the crystal form II has an X-ray powder diffraction pattern comprising diffraction peaks at 11.32±0.20°, 11.70±0.20°, 11.93±0.20°, 18.03±0.20°, 18.81±0.20°, and 19.17±0.20°, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles;

### Claim 5 (depends on 4)

The crystal form II according to claim 4, wherein the crystal form II satisfies one or more of the following conditions:
(1) the X-ray powder diffraction pattern of the crystal form II, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, further comprises diffraction peaks at one or more of the following positions: 5.54±0.20°, 12.37±0.20°, 13.78±0.20°, 14.11±0.20°, 15.78±0.20°, and 20.80±0.20°;
(2) the X-ray powder diffraction pattern of the crystal form II, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks at one or more of the following positions: 5.54±0.20°, 12.37±0.20°, 13.55±0.20°, 13.78±0.20°, 14.11±0.20°, 15.78±0.20° 16.40±0.20°, 17.74±0.20°, 20.49±0.20°, and 20.80±0.20° and 22.06±0.20°;
(3) the X-ray powder diffraction pattern of the crystal form II, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks at 5.54±0.20°, 11.32±0.20°, 11.70±0.20°, 11.93±0.20°, 12.37±0.20°, 13.55±0.20°, 13.78±0.20°, 14.11±0.20°, 15.78±0.20°, 16.40±0.20°, 17.74±0.20°, 18.03±0.20°, 18.81±0.20°, 19.17±0.20°, 20.49±0.20°, 20.80±0.20°, and 22.06±0.20°;
(4) the X-ray powder diffraction pattern of the crystal form II, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks at positions as shown in the following table:
Position in
No.
2θ (°)
1
5.54
2
7.20
3
8.63
4
9.04
5
11.32
6
11.70
7
11.93
8
12.37
9
12.80
10
13.55
11
13.78
12
14.11
13
14.52
14
15.23
15
15.78
16
16.40
17
16.92
18
17.31
19
17.74
20
18.03
21
18.41
22
18.81
23
19.17
24
19.68
25
20.21
26
20.49
27
20.80
28
21.23
29
22.06
30
22.52
31
23.15
32
23.54
33
24.44
34
24.78
35
25.33
36
25.92
37
26.40
38
26.68
39
27.52
40
28.36
41
29.62
42
30.06
43
31.61
44
34.52;
(5) the X-ray powder diffraction pattern of the crystal form II, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, comprises diffraction peaks with positions and relative intensities as shown in the following table:
Position in
Relative
No.
2θ (°)
intensity
1
5.54
62.50%
2
7.20
4.60%
3
8.63
19.60%
4
9.04
15.80%
5
11.32
64.40%
6
11.70
65.00%
7
11.93
92.80%
8
12.37
64.30%
9
12.80
29.20%
10
13.55
37.70%
11
13.78
57.00%
12
14.11
54.40%
13
14.52
36.10%
14
15.23
36.80%
15
15.78
61.50%
16
16.40
40.10%
17
16.92
25.00%
18
17.31
32.50%
19
17.74
41.80%
20
18.03
95.30%
21
18.41
30.00%
22
18.81
69.20%
23
19.17
100.00%
24
19.68
31.90%
25
20.21
11.00%
26
20.49
48.80%
27
20.80
51.00%
28
21.23
10.40%
29
22.06
50.40%
30
22.52
34.30%
31
23.15
27.40%
32
23.54
16.90%
33
24.44
13.00%
34
24.78
19.60%
35
25.33
11.20%
36
25.92
9.40%
37
26.40
9.00%
38
26.68
8.20%
39
27.52
13.40%
40
28.36
5.40%
41
29.62
6.50%
42
30.06
5.90%
43
31.61
3.80%
44
34.52
5.70%;
(6) the crystal form II has a differential scanning calorimetry pattern comprising an endothermic peak at 230.7±2° C.; and
(7) the crystal form II has a differential scanning calorimetry pattern comprising an exothermic peak at 159.1±2° C.; and
(8) the crystal form II has a thermogravimetric analysis pattern showing a weight loss of 1.71% before 210±2° C.

### Claim 6 (depends on 5)

The crystal form II according to claim 5, wherein the crystal form II satisfies one or more of the following conditions:
(1) the X-ray powder diffraction pattern of the crystal form II, as determined by using Cu-Kα radiation and expressed in terms of 2θ angles, is substantially as shown in FIG. 6;
(2) the differential scanning calorimetry pattern of the crystal form II is substantially as shown in FIG. 7; and
(3) the thermogravimetric analysis pattern of the crystal form II is substantially as shown in FIG. 7.

### Claim 7 (depends on 1)

A preparation method for the crystal form I as defined in claim 1, wherein the preparation method comprises the following steps: dissolving the nitrogen-containing spiro compound of formula A in N-methylpyrrolidone, adding an antisolvent, and crystallizing; wherein the antisolvent is one or more selected from the group consisting of nitrile solvents, ester solvents, benzene solvents, ether solvents, and water.

### Claim 8 (depends on 4)

A preparation method for the crystal form II as defined in claim 4, wherein the preparation method comprises the following steps: stirring the nitrogen-containing spiro compound of formula A in acetonitrile for 12 to 16 days.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising: (1) the crystal form I as defined in claim 1; and
(2) a pharmaceutically acceptable carrier.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method for treating or preventing a disease, comprising administering a therapeutically effective amount of the crystal form I according to claim 1 to a subject in need thereof, wherein the disease is a blood disease, kidney disease, cardiovascular disease, immune disorder, central nervous system disease, respiratory disease, urogenital disease, or ocular disease.

### Claim 12 (depends on 1)

A complement factor D inhibitor, comprising the crystal form I according to claim 1;
the complement factor D inhibitor is used in vivo or in vitro in mammals.

### Claim 13 (depends on 7)

The preparation method according to claim 7, the preparation method for the crystal form I satisfies one or more of the following conditions:
(1) the method for the dissolving is heating with stirring; the temperature for the heating is 30 to 70° C.;
(2) the volume-to-mass ratio of N-methylpyrrolidone to the nitrogen-containing spiro compound of formula A is 15 to 50 mL/g;
(3) the volume-to-mass ratio of the antisolvent to the nitrogen-containing spiro compound of formula A is 50 to 350 mL/g;
(4) the volume ratio of the antisolvent to N-methylpyrrolidone is (1 to 10):1;
(5) a cooling step is further included before adding the antisolvent; the cooling step involves cooling to between 10° C. and 20° C.; the cooling step has a cooling rate of 0.2° C./min;
(6) the nitrile solvent is acetonitrile;
(7) the ester solvent is one or more of ethyl acetate, n-propyl acetate, and isopropyl acetate;
(8) the benzene solvent is one or more of toluene, ethylbenzene, xylene, isopropylbenzene, and chlorobenzene;
(9) the ether solvent is one or more of methyl tert-butyl ether, diethyl ether, cyclopentyl methyl ether, isopropyl ether, methyl tetrahydrofuran, and dioxane.

### Claim 14 (depends on 7)

The preparation method according to claim 7, the preparation method for the crystal form I satisfies one or more of the following conditions:
(1) the method for the dissolving is heating with stirring; the temperature for the heating is 40 to 60° C. or 50° C.;
(2) the volume-to-mass ratio of N-methylpyrrolidone to the nitrogen-containing spiro compound of formula A is 20 to 35 mL/g or 26.7 mL/g;
(3) the volume-to-mass ratio of the antisolvent to the nitrogen-containing spiro compound of formula A is 80 to 250 mL/g or 80 mL/g, 160 mL/g, or 213.3 mL/g;
(4) the volume ratio of the antisolvent to N-methylpyrrolidone is (3 to 8):1 or 3:1, 6:1, or 8:1;
(5) a cooling step is further included before adding the antisolvent; the cooling step involves cooling to between 10° C. and 20° C. or 17° C.; the cooling step has a cooling rate of 0.2° C./min;
(6) the ester solvent is ethyl acetate and/or isopropyl acetate;
(7) the benzene solvent is toluene; and
(8) the ether solvent is methyl tert-butyl ether.

### Claim 15 (depends on 8)

The preparation method according to claim 8, the preparation method for the crystal form II satisfies one or more of the following conditions:
(1) the volume-to-mass ratio of acetonitrile to the nitrogen-containing spiro compound of formula A is 15 to 50 mL/g;
(2) the temperature for the stirring is 15 to 30° C.; and
(3) the time for the stirring is 14 days.

### Claim 16 (depends on 8)

The preparation method according to claim 8, the preparation method for the crystal form II satisfies one or more of the following conditions:
(1) the volume-to-mass ratio of acetonitrile to the nitrogen-containing spiro compound of formula A is 25 to 40 mL/g or 33.3 mL/g;
(2) the temperature for the stirring is 17° C.

### Claim 17 (depends on 4)

A pharmaceutical composition comprising: (1) the crystal form II as defined in claim 4; and
(2) a pharmaceutically acceptable carrier.

### Claim 18 (depends on 11)

The method according to claim 11, wherein the method satisfies one or more of the following conditions:
(1) the disease is a complement factor D-mediated disease;
(2) the disease is cold agglutinin disease, catastrophic antiphospholipid syndrome, hemolytic anemia, anti-neutrophil cytoplasmic antibody-associated vasculitis, warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, IgA nephropathy, lupus nephritis, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, dense deposit disease, C3 glomerulonephritis, focal segmental glomerulosclerosis, diabetic nephropathy, systemic lupus erythematosus or lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis, organ transplant rejection, myasthenia gravis, Alzheimer's disease, respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, emphysema, coronavirus infection, macular degeneration, age-related macular degeneration, macular edema, diabetic macular edema, choroidal neovascularization, uveitis, Behçet's uveitis, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, glaucoma, hypertensive retinopathy, corneal neovascularization, corneal transplant rejection, corneal dystrophy, autoimmune dry eye disease, Stevens-Johnson syndrome, Sjögren's syndrome, environmental dry eye disease, Fuchs' endothelial corneal dystrophy, retinal vein occlusion, or postoperative inflammation; the coronavirus infection is SARS-COV, MERS-COV, or SARS-COV-2 infection.

### Claim 19 (depends on 4)

A method for treating or preventing a disease, comprising administering a therapeutically effective amount of the crystal form II according to claim 4 to a subject in need thereof, wherein the disease is a blood disease, kidney disease, cardiovascular disease, immune disorder, central nervous system disease, respiratory disease, urogenital disease, or ocular disease.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the method satisfies one or more of the following conditions:
(1) the disease is a complement factor D-mediated disease;
(2) the disease is cold agglutinin disease, catastrophic antiphospholipid syndrome, hemolytic anemia, anti-neutrophil cytoplasmic antibody-associated vasculitis, warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, IgA nephropathy, lupus nephritis, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, dense deposit disease, C3 glomerulonephritis, focal segmental glomerulosclerosis, diabetic nephropathy, systemic lupus erythematosus or lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis, organ transplant rejection, myasthenia gravis, Alzheimer's disease, respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, emphysema, coronavirus infection, macular degeneration, age-related macular degeneration, macular edema, diabetic macular edema, choroidal neovascularization, uveitis, Behçet's uveitis, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, glaucoma, hypertensive retinopathy, corneal neovascularization, corneal transplant rejection, corneal dystrophy, autoimmune dry eye disease, Stevens-Johnson syndrome, Sjögren's syndrome, environmental dry eye disease, Fuchs' endothelial corneal dystrophy, retinal vein occlusion, or postoperative inflammation; the coronavirus infection is SARS-COV, MERS-COV, or SARS-COV-2 infection.

### Claim 21 (depends on 4)

A complement factor D inhibitor, comprising the crystal form II according to claim 4;
the complement factor D inhibitor is used in vivo or in vitro in mammals.
